← back to search

Akshay J. Patel

Geisinger Commonwealth School of Medicine · GB
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Lung Cancer Diagnosis and Treatment, Cytokine Signaling Pathways and Interactions, and Lung Cancer Treatments and Mutations.
h-index
36
citations
6,006
works
207
NIH funding
primary concept
Medicine
email

Recent publications

Robotic Thoracic Surgery: Current Landscape and Future Directions.
2026cited by 0position: contributordoi
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Nature Medicine 2025cited by 75position: middledoi
Chest wall resection and reconstruction for primary chest wall sarcomas: Analysis of survival, predictors of outcome, and long-term functional status.
2025cited by 3position: contributordoi
Impact of Hydrogel-Coated Chest Drains on Outcomes in Thoracic Surgery.
2025cited by 0position: contributordoi
Evolving Resection Strategies for Non-Small Cell Lung Cancers: Translating Trial Evidence to Real-World Practice.
2025cited by 0position: contributordoi
Surgical management of complex mediastinitis: an 8-year single-centre experience reinforcing the role of open thoracotomy.
2025cited by 0position: contributordoi
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Nature Communications 2024cited by 42position: middledoi
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Nature Communications 2024cited by 25position: middledoi
Robotic-assisted versus video-assisted thoracoscopic surgery for thymic epithelial tumours, from the European Society of Thoracic Surgeons Database.
2024cited by 5position: contributordoi
Role of vitamin D supplementation in modifying outcomes after surgery: a systematic review of randomised controlled trials.
2024cited by 4position: contributordoi
Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer.
2024cited by 3position: contributordoi
A multi-lesional analysis of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a single-centre analysis.
2024cited by 2position: contributordoi
Absorbable Powder Haemostat Use in Minimally Invasive Thoracic Surgery.
2024cited by 0position: contributordoi
Lung adenocarcinoma promotion by air pollutants
Nature 2023cited by 728position: middledoi
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Nature 2023cited by 327position: middledoi
The evolution of non-small cell lung cancer metastases in TRACERx
Nature 2023cited by 230position: middledoi
Body composition and lung cancer-associated cachexia in TRACERx
Nature Medicine 2023cited by 123position: middledoi
European guidelines for the surgical management of pure ground-glass opacities and part-solid nodules: Task Force of the European Association of Cardio-Thoracic Surgery and the European Society of Thoracic Surgeons
European Journal of Cardio-Thoracic Surgery 2023cited by 45position: middledoi
MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids.
2023cited by 9position: contributordoi
TIGIT-based immunotherapeutics in lung cancer.
2023cited by 6position: contributordoi
Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
Nature Communications 2022cited by 78position: firstdoi
Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade.
2022cited by 44position: contributordoi
VATS surgical anatomical resection of bronchopulmonary sequestration presenting as chest sepsis.
2022cited by 3position: contributordoi
Minimising risk to thoracic surgical teams in an era of COVID-19: exploring possible preventative measures.
2021cited by 0position: contributordoi
Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and health economic analysis plan for the 65 trial in article
Journal of the Intensive Care Society 2020cited by 3position: middledoi
Delayed cardiac tamponade following blunt chest trauma due to disruption of fourth costal cartilage with posterior dislocation.
2020cited by 3position: contributordoi
Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and Health Economic Analysis Plan for the 65 trial
Journal of the Intensive Care Society 2019cited by 4position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Gary Middleton · University of Oxford4 papers (2022–2023)Kathy Rowan · University of Pittsburgh2 papers (2019–2020) · 2 papers (2022–2023) · 2 papers (2022–2023)Zia Sadique · University of Balochistan2 papers (2019–2020)Sophie Papa · The London College2 papers (2022–2022)David A Harrison · Vanderbilt University Medical Center2 papers (2019–2020)Silvia Moler Zapata · London School of Hygiene & Tropical Medicine2 papers (2019–2020)Karen Thomas · Royal Marsden NHS Foundation Trust2 papers (2019–2020)François Lamontagne · Ottawa University2 papers (2019–2020)Alexina J. Mason · London School of Hygiene & Tropical Medicine2 papers (2019–2020)Mark T. Drayson · Institute of Immunology2 papers (2022–2022)Anthony Gordon · Imperial College Healthcare NHS Trust2 papers (2019–2020)Paul Mouncey · University Hospitals Plymouth NHS Trust2 papers (2019–2020)Joel Dunning · Roswell Park Comprehensive Cancer Center1 papers (2023–2023) · 1 papers (2023–2023)Eric Lim · Royal Brompton & Harefield NHS Foundation Trust1 papers (2023–2023)Alessandro Brunelli · University of Ferrara1 papers (2023–2023)Zena Willsmore · King's College London1 papers (2022–2022)Andrew Cope · King's College London1 papers (2022–2022)